pioglitazone has been researched along with Adverse Drug Event in 23 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The pioglitazone was effective in reducing plasma glucose and HbA1c from the baseline levels from Week 4 onward." | 2.73 | Combination therapy of pioglitazone with voglibose improves glycemic control safely and rapidly in Japanese type 2-diabetic patients on hemodialysis. ( Abe, M; Kaizu, K; Kikuchi, F; Matsumoto, K, 2007) |
| " Withdrawal due to lack of efficacy or adverse events occurred more frequently with glyburide (20." | 2.72 | Long-term safety of pioglitazone versus glyburide in patients with recently diagnosed type 2 diabetes mellitus. ( Jain, R; Kupfer, S; Osei, K; Perez, AT; Zhang, J, 2006) |
| " Reporting of CTs and adverse drug reactions to Clinical Trials Registry of India and Pharmacovigilance Programme of India, respectively, along with compliance studies with warning given in package insert and epidemiological studies with larger sample size are needed." | 2.53 | Pioglitazone utilization, efficacy & safety in Indian type 2 diabetic patients: A systematic review & comparison with European Medicines Agency Assessment Report. ( Kshirsagar, NA; Pai, SA, 2016) |
| " They provide similar effects on glycemic control, as well as a range of similar adverse effects, such as weight gain, fluid retention, and increased risk of hearth failure, which seem to be PPARγ mediated." | 2.48 | Update on cardiovascular safety of PPARgamma agonists and relevance to medicinal chemistry and clinical pharmacology. ( Ciudin, A; Hernandez, C; Simó, R, 2012) |
| " The potential concomitant changes in the reporting of adverse reactions concerning these alternatives have been studied less often." | 1.46 | Impact of Medicine Withdrawal on Reporting of Adverse Events Involving Therapeutic Alternatives: A Study from the French Spontaneous Reporting Database. ( Arnaud, M; Bégaud, B; Bezin, J; Haramburu, F; Pageot, C; Pariente, A; Salvo, F; Smith, A, 2017) |
| "Pioglitazone was further assessed as a mechanism-based inhibitor." | 1.40 | Domperidone interacts with pioglitazone but not with ondansetron via common CYP metabolism in vitro. ( Nagar, S; Parkman, HP; Youssef, AS, 2014) |
| " We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts." | 1.37 | FDA-approved drug labeling for the study of drug-induced liver injury. ( Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (13.04) | 29.6817 |
| 2010's | 20 (86.96) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, M | 1 |
| Vijay, V | 1 |
| Shi, Q | 2 |
| Liu, Z | 2 |
| Fang, H | 2 |
| Tong, W | 2 |
| Dawson, S | 1 |
| Stahl, S | 1 |
| Paul, N | 1 |
| Barber, J | 1 |
| Kenna, JG | 1 |
| Ding, D | 1 |
| Kelly, R | 1 |
| Sakatis, MZ | 1 |
| Reese, MJ | 1 |
| Harrell, AW | 1 |
| Taylor, MA | 1 |
| Baines, IA | 1 |
| Chen, L | 1 |
| Bloomer, JC | 1 |
| Yang, EY | 1 |
| Ellens, HM | 1 |
| Ambroso, JL | 1 |
| Lovatt, CA | 1 |
| Ayrton, AD | 1 |
| Clarke, SE | 1 |
| Morgan, RE | 1 |
| van Staden, CJ | 1 |
| Chen, Y | 1 |
| Kalyanaraman, N | 1 |
| Kalanzi, J | 1 |
| Dunn, RT | 1 |
| Afshari, CA | 1 |
| Hamadeh, HK | 1 |
| Pai, SA | 1 |
| Kshirsagar, NA | 1 |
| Pageot, C | 1 |
| Bezin, J | 1 |
| Smith, A | 1 |
| Arnaud, M | 1 |
| Salvo, F | 1 |
| Haramburu, F | 1 |
| Bégaud, B | 1 |
| Pariente, A | 1 |
| Schernthaner, G | 1 |
| Currie, CJ | 1 |
| Schernthaner, GH | 1 |
| Youssef, AS | 1 |
| Parkman, HP | 1 |
| Nagar, S | 1 |
| Dangi-Garimella, S | 1 |
| Winnenburg, R | 1 |
| Shah, NH | 1 |
| Hostenkamp, G | 1 |
| Fischer, KE | 1 |
| Borch-Johnsen, K | 1 |
| Ruaño, G | 1 |
| Bernene, J | 1 |
| Windemuth, A | 1 |
| Bower, B | 1 |
| Wencker, D | 1 |
| Seip, RL | 1 |
| Kocherla, M | 1 |
| Holford, TR | 1 |
| Petit, WA | 1 |
| Hanks, S | 1 |
| Vlckova, V | 1 |
| Cornelius, V | 1 |
| Kasliwal, R | 1 |
| Wilton, L | 1 |
| Shakir, S | 1 |
| Hall, GC | 1 |
| Smith, HT | 1 |
| Curtis, B | 1 |
| McMahon, AD | 1 |
| Ciudin, A | 1 |
| Hernandez, C | 1 |
| Simó, R | 1 |
| Lenzer, J | 1 |
| Banerjee, S | 1 |
| Mohan, V | 1 |
| Bedi, S | 1 |
| Unnikrishnan, R | 1 |
| Sahay, BK | 1 |
| Joshpi, S | 1 |
| Misra, A | 1 |
| Panikar, V | 1 |
| Jain, R | 1 |
| Osei, K | 1 |
| Kupfer, S | 1 |
| Perez, AT | 1 |
| Zhang, J | 1 |
| Abe, M | 1 |
| Kikuchi, F | 1 |
| Kaizu, K | 1 |
| Matsumoto, K | 1 |
3 reviews available for pioglitazone and Adverse Drug Event
| Article | Year |
|---|---|
Pioglitazone utilization, efficacy & safety in Indian type 2 diabetic patients: A systematic review & comparison with European Medicines Agency Assessment Report.
Topics: Clinical Trials as Topic; Diabetes Mellitus, Type 2; Drug-Related Side Effects and Adverse Reactions | 2016 |
Update on cardiovascular safety of PPARgamma agonists and relevance to medicinal chemistry and clinical pharmacology.
Topics: Animals; Cardiovascular Diseases; Chemistry, Pharmaceutical; Drug-Related Side Effects and Adverse R | 2012 |
Pioglitazone--where do we stand in India?
Topics: Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Rela | 2012 |
2 trials available for pioglitazone and Adverse Drug Event
| Article | Year |
|---|---|
Long-term safety of pioglitazone versus glyburide in patients with recently diagnosed type 2 diabetes mellitus.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Drug-Related Side Effects and | 2006 |
Combination therapy of pioglitazone with voglibose improves glycemic control safely and rapidly in Japanese type 2-diabetic patients on hemodialysis.
Topics: Aged; Asian People; Blood Glucose; Case-Control Studies; Demography; Diabetes Mellitus, Type 2; Drug | 2007 |
18 other studies available for pioglitazone and Adverse Drug Event
| Article | Year |
|---|---|
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Des | 2011 |
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters | 2012 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
Topics: Animals; Anti-Infective Agents; Anti-Inflammatory Agents; Chemical and Drug Induced Liver Injury; Da | 2011 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily | 2013 |
Impact of Medicine Withdrawal on Reporting of Adverse Events Involving Therapeutic Alternatives: A Study from the French Spontaneous Reporting Database.
Topics: Adverse Drug Reaction Reporting Systems; Benzodiazepines; Databases, Factual; Dextropropoxyphene; Dr | 2017 |
Do we still need pioglitazone for the treatment of type 2 diabetes? A risk-benefit critique in 2013.
Topics: Biomarkers; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug-Related Side Effects and Advers | 2013 |
Domperidone interacts with pioglitazone but not with ondansetron via common CYP metabolism in vitro.
Topics: Antiemetics; Chromatography, Liquid; Cytochrome P-450 CYP3A; Domperidone; Drug Interactions; Drug-Re | 2014 |
The Yin and the Yang of CV risks in patients with diabetes.
Topics: Adamantane; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dipeptides | 2014 |
Generalized enrichment analysis improves the detection of adverse drug events from the biomedical literature.
Topics: Animals; Computational Biology; Drug-Related Side Effects and Adverse Reactions; Humans; Hypoglycemi | 2016 |
Drug safety and the impact of drug warnings: An interrupted time series analysis of diabetes drug prescriptions in Germany and Denmark.
Topics: Denmark; Diabetes Mellitus, Type 2; Drug Interactions; Drug Labeling; Drug Prescriptions; Drug Utili | 2016 |
Physiogenomic comparison of edema and BMI in patients receiving rosiglitazone or pioglitazone.
Topics: Adult; Aged; Aged, 80 and over; Body Mass Index; Cross-Sectional Studies; Drug-Related Side Effects | 2009 |
Effective approach.
Topics: Diabetes Mellitus; Drug Approval; Drug-Related Side Effects and Adverse Reactions; Health Care Ratio | 2010 |
Hypoglycaemia with pioglitazone: analysis of data from the Prescription-Event Monitoring study.
Topics: Adverse Drug Reaction Reporting Systems; Aged; Diabetes Mellitus, Type 2; Drug-Related Side Effects | 2010 |
Changes and predictors for change to thiazolidinedione prescribing in UK primary care following the rosiglitazone safety warning.
Topics: Adult; Aged; Diabetes Mellitus, Type 2; Drug Substitution; Drug-Related Side Effects and Adverse Rea | 2011 |
Whistleblower lawsuit claims Takeda concealed harms of diabetes drug.
Topics: Diabetes Mellitus; Drug-Related Side Effects and Adverse Reactions; Humans; Hypoglycemic Agents; Man | 2012 |
Pioglitazone safe, so save.
Topics: Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug | 2012 |
Pioglitazone and bladder cancer: the pros and cons.
Topics: Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug-Rela | 2012 |